LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+9.87%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$893M
AUM Growth
+$893M
(+2.9%)
Cap. Flow
-$359M
Cap. Flow
% of AUM
-40.21%
Top 10 Holdings %
Top 10 Hldgs %
48.42%
Holding
67
New
14
Increased
9
Reduced
18
Closed
12
Top Buys
| 1 |
Vaxcyte
PCVX
|
$34.3M |
| 2 |
Celldex Therapeutics
CLDX
|
$30.6M |
| 3 |
Galapagos
GLPG
|
$23M |
| 4 |
Cogent Biosciences
COGT
|
$21.6M |
| 5 |
Cytokinetics
CYTK
|
$21.1M |
Top Sells
| 1 |
CYBN
Cybin
CYBN
|
$350M |
| 2 |
argenx
ARGX
|
$58.1M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$33M |
| 4 |
Xencor
XNCR
|
$28.4M |
| 5 |
SLN
Silence Therapeutics
SLN
|
$23.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
IDEAYA Biosciences
IDYA
$2.15B
| $66.5M | 7.18% | 2,100,000 +400,000 | +24% | +$12.7M |
|
2
Structure Therapeutics
GPCR
$1.11B
| $54.9M | 5.92% | 1,250,000 +150,000 | +14% | +$6.58M |
|
3
Revolution Medicines
RVMD
$7.1B
| $54.4M | 5.87% | 1,200,000 | – | – |
|
4
Disc Medicine
IRON
$2.07B
| $45.9M | 4.96% | 935,000 +10,000 | +1% | +$491K |
|
5
Janux Therapeutics
JANX
$1.37B
| $45.4M | 4.9% | 1,000,000 +250,000 | +33% | +$11.4M |
|
6
Olema Pharmaceuticals
OLMA
$375M
| $38.3M | 4.13% | 3,208,875 | – | – |
|
|
7
Vaxcyte
PCVX
$4B
| $34.3M | 3.7% | +300,000 | New | +$34.3M |
|
8
Immunovant
IMVT
$2.56B
| $31.4M | 3.38% | 1,100,000 +525,000 | +91% | +$15M |
|
|
9
Celldex Therapeutics
CLDX
$1.47B
| $30.6M | 3.3% | +900,000 | New | +$30.6M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $30.5M | 3.29% | 3,500,000 -1,650,000 | -32% | -$14.4M |
|
11
Ionis Pharmaceuticals
IONS
$6.8B
| $30M | 3.24% | 750,000 +450,000 | +150% | +$18M |
|
12
Erasca
ERAS
$445M
| $29.8M | 3.21% | 10,900,000 +5,000,000 | +85% | +$13.7M |
|
13
Merus
MRUS
$4.98B
| $28.7M | 3.1% | 575,000 -275,000 | -32% | -$13.7M |
|
|
14
Galapagos
GLPG
$2.07B
| $23M | 2.49% | +800,000 | New | +$23M |
|
15
Akero Therapeutics
AKRO
$3.74B
| $23M | 2.48% | 800,000 | – | – |
|
16
Design Therapeutics
DSGN
$315M
| $22.7M | 2.45% | 4,217,627 -814,874 | -16% | -$4.38M |
|
17
Vera Therapeutics
VERA
$1.38B
| $22.1M | 2.38% | 500,000 -450,000 | -47% | -$19.9M |
|
|
18
Cogent Biosciences
COGT
$1.69B
| $21.6M | 2.33% | +2,000,000 | New | +$21.6M |
|
|
19
Cytokinetics
CYTK
$4.23B
| $21.1M | 2.28% | +400,000 | New | +$21.1M |
|
|
BCAX
20
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $20.4M | 2.2% | +800,000 | New | +$20.4M |
|
21
Sarepta Therapeutics
SRPT
$1.78B
| $18.7M | 2.02% | 150,000 | – | – |
|
22
Annexon
ANNX
$226M
| $15.4M | 1.66% | 2,600,000 -700,000 | -21% | -$4.14M |
|
23
Travere Therapeutics
TVTX
$1.56B
| $15.4M | 1.66% | +1,100,000 | New | +$15.4M |
|
24
Enliven Therapeutics
ELVN
$1.2B
| $12.6M | 1.36% | 495,000 -100,000 | -17% | -$2.55M |
|
25
Beam Therapeutics
BEAM
$1.66B
| $12.3M | 1.32% | +500,000 | New | +$12.3M |
|